MiniMed Group, the diabetes technology division carved out of medical device giant Medtronic, priced its U.S. initial public offering at $20 per share, below the previously expected range of $25 to $28. The offering raised $560 million through the sale of 28 million shares and values the company at approximately $5.6 billion.

The IPO marks one of the most significant healthcare carve-outs in the medical device sector in recent years, giving investors direct exposure to a rapidly growing diabetes technology platform centered on insulin delivery and glucose monitoring solutions.

Company Background

MiniMed Group specializes in integrated diabetes management technologies designed to help patients monitor glucose levels and administer insulin more effectively. The company was created as a carve-out of Medtronic’s diabetes management business, allowing the unit to operate independently and focus exclusively on innovation and growth within the diabetes care market.

The company’s core product portfolio includes insulin pumps, continuous glucose monitoring systems, infusion sets, reservoirs, insulin pen systems, and digital health platforms that connect devices with software-based data management tools. These integrated systems allow patients and healthcare providers to track glucose levels in real time and optimize insulin dosing.

MiniMed’s technology ecosystem has built a large installed user base, with more than 640,000 individuals using its insulin pump systems as of October 2025. A key growth driver for the company is the increasing adoption of continuous glucose monitors, which integrate with insulin delivery devices to create automated diabetes management systems.

The company’s CGM attachment rate reached 65% in the six months ended October 24, 2025, up from 58% in the prior period, reflecting rising demand for connected diabetes management solutions.

IPO Details

MiniMed raised $560 million by offering 28 million shares at $20 each, pricing the deal below the expected $25 to $28 range. Despite the lower pricing, the IPO still places the company’s market capitalization at approximately $5.6 billion.

The company plans to list on the Nasdaq under the ticker symbol MMED. The offering was supported by a large syndicate of major investment banks, including Goldman Sachs, BofA Securities, Citi, Morgan Stanley, Barclays, Deutsche Bank, Mizuho Securities, Wells Fargo Securities, Evercore ISI, and Piper Sandler, which served as joint bookrunners.

The IPO provides MiniMed with capital to invest in product development, global expansion, and next-generation diabetes technologies while allowing its former parent company Medtronic to streamline its business structure.

Market Context & Opportunities

The diabetes care market represents one of the fastest-growing segments in healthcare, driven by the global rise in diabetes diagnoses and increasing demand for digital health technologies that improve disease management.

Technological advances in insulin delivery and glucose monitoring have transformed diabetes care, shifting treatment toward automated systems that combine insulin pumps with real-time glucose sensors. These integrated platforms can significantly improve patient outcomes by maintaining tighter glucose control while reducing the burden of manual monitoring.

MiniMed’s business model also benefits from recurring revenue streams tied to consumables, software services, and sensor replacements. Approximately 83% of the company’s revenue is generated from CGMs, consumables, and related services, creating a steady stream of recurring income beyond initial device sales.

As healthcare systems increasingly adopt digital health tools and remote monitoring technologies, companies operating in diabetes technology are positioned for long-term growth.

Risks & Challenges

Despite its strong position in diabetes technology, MiniMed faces intense competition from other major medical device companies and emerging digital health innovators developing alternative insulin delivery and glucose monitoring systems.

Pricing pressure from healthcare systems, insurance providers, and government reimbursement programs could also impact margins across the diabetes care sector.

Additionally, medical device companies must navigate strict regulatory approval processes, quality standards, and ongoing product safety monitoring. Any manufacturing issues or device recalls could affect the company’s reputation and financial performance.

Closing Paragraph 

MiniMed’s IPO marks a significant step in the evolution of Medtronic’s diabetes technology business, transforming the unit into a standalone company focused on one of the largest chronic disease markets in healthcare.

While pricing below the expected range may signal cautious investor sentiment, MiniMed enters the public market with a substantial installed user base, a recurring revenue model, and exposure to the expanding global diabetes care market. The company’s ability to innovate and compete in the rapidly evolving digital health landscape will determine whether the carve-out becomes a major standalone player in medical technology.